Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Jason M. Foulks"'
Autor:
Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Guo Ge, Lyndsey Bolanos, Mark Wunderlich, Johann-Christoph Jann, Alina Wein, Eva Altrock, Marie Demmerle, Sanjay Mukherjee, Abdullah Mahmood Ali, Felicitas Rapp, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Melda Göl, Ahmed Jawhar, Ali Darwich, Patrick Wuchter, Christel Weiss, Azra Raza, Jason M. Foulks, Daniel T. Starczynowski, Feng-Chun Yang, Georgia Metzgeroth, Laurenz Steiner, Mohamad Jawhar, Wolf-Karsten Hofmann, Daniel Nowak
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cycl
Externí odkaz:
https://doaj.org/article/587fe7bf73e84c44b2b804ab4433a656
Autor:
Tsz-Yin Chan, Christina M. Egbert, Julia E. Maxson, Adam Siddiqui, Logan J. Larsen, Kristina Kohler, Eranga Roshan Balasooriya, Katie L. Pennington, Tsz-Ming Tsang, Madison Frey, Erik J. Soderblom, Huimin Geng, Markus Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, Courtney J. Banks, Jonard Valdoz, Clifford J. Whatcott, Jason M. Foulks, David J. Bearss, Thomas O’Hare, David C. S. Huang, Kenneth A. Christensen, James Moody, Steven L. Warner, Jeffrey W. Tyner, Joshua L. Andersen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
The mechanisms underlying the activity of non-receptor tyrosine kinase, TNK1, in cancers are unclear. Here the authors show that MARK mediates 14-3-3 and TNK1 interaction which restrains TNK1 activity, while the release of TNK1 from 14-3-3 leads to T
Externí odkaz:
https://doaj.org/article/3bf3573d63094261ac7abe05b09d7ee9
Autor:
Jason M. Foulks, Kent J. Carpenter, Bai Luo, Yong Xu, Anna Senina, Rebecca Nix, Ashley Chan, Adrianne Clifford, Marcus Wilkes, David Vollmer, Benjamin Brenning, Shannon Merx, Shuping Lai, Michael V. McCullar, Koc-Kan Ho, Daniel J. Albertson, Lee T. Call, Jared J. Bearss, Sheryl Tripp, Ting Liu, Bret J. Stephens, Alexis Mollard, Steven L. Warner, David J. Bearss, Steven B. Kanner
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 5, Pp 403-412 (2014)
The proto-oncogene proviral integration site for moloney murine leukemia virus (PIM) kinases (PIM-1, PIM-2, and PIM-3) are serine/threonine kinases that are involved in a number of signaling pathways important to cancer cells. PIM kinases act in down
Externí odkaz:
https://doaj.org/article/f6e9436c49d74639b522a5830ff2bb3f
Autor:
Jiawei Chen, Lili Yang, Jason M. Foulks, Andrew S. Weyrich, Gopal K. Marathe, Thomas M. McIntyre
Publikováno v:
Journal of Lipid Research, Vol 48, Iss 11, Pp 2365-2376 (2007)
Stimulated inflammatory cells synthesize platelet-activating factor (PAF), but lysates of these cells show little enhancement in PAF synthase activity. We show that human neutrophils contain intracellular plasma PAF acetylhydrolase (PLA2G7), an enzym
Externí odkaz:
https://doaj.org/article/c7360768e04b4b9cab4c3d1314dc50aa
Publikováno v:
Medicinal Chemistry Research. 31:1068-1087
The druggable genome is limited by structural features that can be targeted by small molecules in disease-relevant proteins. While orthosteric and allosteric protein modulators have been well studied, they are limited to antagonistic/agonistic functi
Autor:
Steven B. Kanner, Koc-Kan Ho, Michael V. McCullar, Marc O'Reilly, Kevin Wright, Scott Pearce, Xiao-Hui Liu, Michael Saunders, Yong Xu, Virgil McCarthy, Jihua Liu, David Vollmer, Anna Senina, Bai Luo, Jeremy Bullough, Adrianne Clifford, Rebecca N. Nix, Jason M. Foulks, K. Mark Parnell
Inactivation of the M2 form of pyruvate kinase (PKM2) in cancer cells is associated with increased tumorigenicity. To test the hypothesis that tumor growth may be inhibited through the PKM2 pathway, we generated a series of small-molecule PKM2 activa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1681cbb614c99d18db4a719f8206e70
https://doi.org/10.1158/1535-7163.c.6536250
https://doi.org/10.1158/1535-7163.c.6536250
Autor:
Rolf A. Brekken, Jason M. Foulks, Steven L. Warner, Huocong Huang, Jason E. Toombs, Ali Rizvi, Emily N. Arner, Yuqing Zhang
Supplementary figures show the efficacy of TP-0903 and its effects on tumor infiltrating immune cells and EMT markers expression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b35f8e3f35bd872f4b714209c15c10b
https://doi.org/10.1158/1535-7163.22522456.v1
https://doi.org/10.1158/1535-7163.22522456.v1
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
Autor:
Steven B. Kanner, Koc-Kan Ho, Michael V. McCullar, Marc O'Reilly, Kevin Wright, Scott Pearce, Xiao-Hui Liu, Michael Saunders, Yong Xu, Virgil McCarthy, Jihua Liu, David Vollmer, Anna Senina, Bai Luo, Jeremy Bullough, Adrianne Clifford, Rebecca N. Nix, Jason M. Foulks, K. Mark Parnell
Supplementary Figure Legends - PDF file 41K, Legends for supplemental figures 1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06832d9dfe0e27d733354edca60423ca
https://doi.org/10.1158/1535-7163.22499760
https://doi.org/10.1158/1535-7163.22499760
Autor:
Steven B. Kanner, Koc-Kan Ho, Michael V. McCullar, Marc O'Reilly, Kevin Wright, Scott Pearce, Xiao-Hui Liu, Michael Saunders, Yong Xu, Virgil McCarthy, Jihua Liu, David Vollmer, Anna Senina, Bai Luo, Jeremy Bullough, Adrianne Clifford, Rebecca N. Nix, Jason M. Foulks, K. Mark Parnell
Supplementary Figures 1-4 - PDF file 294K, Supplementary Figure 1: PKM2 activation by screening hit XC-409; Supplementary Figure 2: Phosphorylation state of PKM2 at Tyr105 in cancer cell lines; supplementary Figure 3: Viability of a selection of lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a47597581c335365308895b32c34bb
https://doi.org/10.1158/1535-7163.22499757
https://doi.org/10.1158/1535-7163.22499757
Autor:
Rolf A. Brekken, Jason M. Foulks, Steven L. Warner, Huocong Huang, Jason E. Toombs, Ali Rizvi, Emily N. Arner, Yuqing Zhang
Pancreatic cancer is the third leading cause of cancer-related deaths in the United States with a 5-year survival less than 5%. Resistance to standard therapy and limited response to immune checkpoint blockade due to the immunosuppressive and stroma-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0a0079a727f282df95fa2a1a26fba4
https://doi.org/10.1158/1535-7163.c.6543388
https://doi.org/10.1158/1535-7163.c.6543388